What do Val/Val, Val/Met, and Met/Met genotypes mean?

Val/Val (GG) means faster COMT activity and lower dopamine tone — better acute-stress performance but poorer working memory. Met/Met (AA) means slower activity and higher dopamine — better executive function but greater stress vulnerability. Val/Met (GA) is intermediate between the two.

Is one COMT genotype better than another?

No. Each genotype has trade-offs: Val/Val offers stress resilience but lower baseline dopamine, Met/Met supports cognition but increases anxiety risk, and Val/Met is balanced. The 'best' genotype depends on context and environment.

How is the sample collected?

The test uses a buccal swab collected at home. Patients rinse the mouth, wait 30 minutes without eating or drinking, then swab the inside of each cheek and return the kit by post.

Can medications or supplements change my COMT genotype?

No. Genotype is fixed at conception. However, COMT enzyme activity can be influenced by magnesium, methylation status, green tea catechins, and pharmaceutical COMT inhibitors — these affect function, not the underlying DNA sequence.

Does COMT genotype affect medication responses?

Yes, in some cases. COMT variants influence responses to L-DOPA, COMT inhibitors, stimulants, and oestrogen therapy. Met/Met individuals may be more sensitive to dopaminergic drugs, while Val/Val may require higher doses for effect.

Is this test a diagnostic genetic test?

No. COMT testing is a pharmacogenomic and functional tool used to personalise interventions. It does not diagnose disease, and results should be integrated with clinical presentation rather than treated as deterministic.

How long do results take?

Genetic analysis typically takes 10–14 business days from the time Cell Science Systems receives the specimen.

What about data privacy and genetic information?

COMT is a single-gene functional polymorphism test, not whole-genome sequencing. Even so, informed consent should address how genetic data are stored, whether they are shared, and the patient's rights. Cell Science Systems' data-privacy policies should be reviewed before ordering.

BML-GEN-016genetic testingUSA

COMT Genetic Test

The COMT genetic test identifies the rs4680 Val158Met polymorphism, a functional variant that modulates catechol-O-methyltransferase activity and thus the speed of dopamine, adrenaline, and catechol oestrogen degradation. Val/Val (GG) confers faster clearance, Met/Met (AA) slower clearance, and Val/Met (GA) intermediate function;

Biomarkers

Buccal swab

Sample

10–14 business days

Turnaround

Fasting

What is the COMT test?

The COMT Genetic Test identifies a patient's rs4680 genotype, a functional variant that modulates the speed of catecholamine degradation and thus influences dopamine availability in the prefrontal cortex and peripheral tissues. Practitioners order this test to stratify patients for personalised interventions — informing choices around stimulant sensitivity, methylation support, stress-management strategies, and selection of nutrients or botanicals that interact with catecholamine pathways. Because COMT sits at the intersection of neurotransmitter metabolism, oestrogen detoxification, and methylation biochemistry, its genotype is relevant across mood and cognitive complaints, hormone-related conditions, chronic pain, and responses to medications such as L-DOPA or stimulants. This is a pharmacogenomic and functional tool rather than a diagnostic genetic test; it does not diagnose disease but adds a layer of biological context to guide therapeutic precision.

What does the COMT test measure?

COMT rs4680(Catechol-O-Methyltransferase Val158Met Polymorphism)

Range: Results reported as GG (Val/Val), GA (Val/Met), or AA (Met/Met); population frequency varies by ancestry.Optimal: There is no 'optimal' COMT genotype; each variant confers trade-offs in cognitive performance, stress response, and pain perception. Clinical application is exploratory and individualised.Genotype

Catechol-O-methyltransferase is a phase-II enzyme that catalyses the transfer of a methyl group from S-adenosylmethionine to catechol substrates, thereby inactivating catecholamines — dopamine, adrenaline, and noradrenaline — and catechol oestrogens. The rs4680 single-nucleotide polymorphism causes a valine-to-methionine substitution at codon 158 of the membrane-bound isoform (codon 108 of the cytosolic form). The Val158 variant exhibits roughly three- to four-fold higher enzymatic activity at physiological temperature than Met158, leading to faster degradation of dopamine in the prefrontal cortex and other tissues. This SNP is one of the most extensively studied functional polymorphisms in neuroscience and pharmacogenomics.

COMT genotype is used in personalised and functional-medicine contexts to inform hypotheses about dopamine tone, stress resilience, and responses to catecholamine-active compounds. The Val/Val (GG) genotype is associated with faster dopamine clearance — a phenotype sometimes labelled 'warrior' for its link to better performance under acute stress but poorer working memory and higher pain sensitivity. The Met/Met (AA) genotype results in slower dopamine breakdown — a 'worrier' profile characterised by higher basal prefrontal dopamine, better executive function under low-stress conditions, but greater vulnerability to chronic stress and anxiety. Heterozygotes (Val/Met, GA) fall between the two homozygous phenotypes. Practitioners use this information to tailor lifestyle, nutraceutical, and medication strategies, though COMT genotype is neither diagnostic nor prescriptive and must be integrated with clinical presentation.

Why is the COMT test ordered?

Patients with treatment-resistant anxiety, mood instability, or attention difficulties where catecholamine tone may play a role
Individuals reporting paradoxical responses to stimulants, methylated B vitamins, or catecholamine-active supplements
Chronic pain syndromes — fibromyalgia, migraine, or neuropathic pain — where COMT variants influence pain perception and opioid requirements
Women with oestrogen-dominant symptoms or difficult-to-manage premenstrual dysphoric disorder, given COMT's role in catechol oestrogen clearance
Personalised medicine assessments integrating cognitive performance, stress resilience, and methylation capacity
Patients considering or already using L-DOPA, COMT inhibitors, or methyl-donor supplementation, where genotype may inform dosing and tolerance
Athletes or high-stress professionals seeking to optimise performance and recovery strategies based on individual dopamine dynamics

Sample collection and turnaround

Sample type

Buccal swab

Fasting required

Collection method

At-home collection kit

Turnaround

10–14 business days

Collection notes

Patient self-collection using a buccal swab kit supplied by Cell Science Systems. The patient should rinse the mouth with water, wait 30 minutes without eating, drinking, or smoking, then firmly swab the inside of each cheek for 30–60 seconds per the kit instructions. Swabs are returned by post in the provided prepaid envelope.

Specimen requirements

Two buccal swabs per kit, air-dried and returned in the protective sleeve. DNA yield is usually adequate from normal epithelial turnover; excessive force is not required.

What can affect COMT results?

variableSample contamination or inadequate buccal cell yield

Insufficient DNA or contamination with food, drink, or foreign DNA can produce a failed or indeterminate result; patients should rinse the mouth and avoid eating, drinking, or smoking for 30 minutes before collection.

variableRecent blood transfusion or bone-marrow transplant

Buccal epithelium reflects the patient's germline genotype, but if donor cells are shed in saliva or if there is chimaerism, results may be confounded; defer testing until stable engraftment or use an alternative tissue source.

variableConcomitant medications and supplements

COMT activity is influenced by magnesium (a cofactor), SAMe availability, and inhibitors such as green tea catechins or entacapone, but these do not alter germline genotype — only its phenotypic expression.

variableAncestry and population stratification

Allele frequencies differ by ancestry (Met allele is more common in Asian populations, Val in African populations), which affects prior probability but not the patient's individual genotype.

variableGene–gene and gene–environment interactions

COMT phenotype is modulated by other genes (MAO-A, DBH, DRD2), oestrogen status, stress load, and diet, so genotype alone does not fully predict function.

What do COMT results mean?

Elevated

Not applicable — COMT testing reports genotype, not enzyme activity or catecholamine levels.

Normal

Not applicable — COMT testing reports genotype (GG, GA, or AA), each of which represents a different but non-pathological functional variant.

Reduced

Not applicable — COMT testing reports genotype, not enzyme activity or catecholamine levels.

Note: Results are genotypes, not diagnoses. Val/Val (GG) predicts faster dopamine clearance, Met/Met (AA) slower clearance, and Val/Met (GA) intermediate activity. Phenotype is probabilistic and influenced by other genes, sex hormones, magnesium status, and environmental factors. This test informs personalised strategies but does not replace clinical assessment, and recommendations should be framed as exploratory rather than deterministic. Informed consent regarding data privacy and the non-diagnostic nature of the test is essential.

Frequently asked questions

The COMT gene encodes catechol-O-methyltransferase, an enzyme that breaks down dopamine, adrenaline, noradrenaline, and catechol oestrogens. The Val158Met variant determines how fast this happens, influencing cognitive performance, stress response, pain sensitivity, and hormone metabolism.

How to access the COMT test

The COMT reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.

Create Free Account

About this page

Published: October 7, 2026

Last reviewed: October 7, 2026

References:

Chen J, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet. (2004)
Mier D, et al. Evidence for altered COMT function: fMRI study of the Val158Met polymorphism. Neuropsychopharmacology. (2010)
Stein DJ, et al. Warriors versus worriers: the role of COMT gene variants. CNS Spectr. (2006)
Diatchenko L, et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet. (2005)
European Society of Human Genetics recommendations for reporting of secondary findings in clinical exome and genome sequencing. (2023)

This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.